Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Steptoe Therapeutics Technology Presented at Meeting of the ASRM Conjoint with the Meeting of the International Federation of Fertility Societies (IFFS) (Boston, MA)
  • USA - English


News provided by

Steptoe Therapeutics, Inc.

Oct 15, 2013, 07:05 ET

Share this article

Share toX

Share this article

Share toX

Boston, Mass. (PRWEB) October 15, 2013 -- Steptoe Therapeutics, Inc., a small biotech private company focused on the development of new treatments for infertility, announced today the presentation of clinical results regarding the use of a cytokine in combination with clomiphene citrate (CC), the most popular fertility drug used for infertility. The abstract (P-384) authored by Dr. Fujii (Kanazawa Medical University, Japan) and collaborators includes the technology covered by US Patent 8,183,205B2 (‘205 Patent) exclusively licensed to Steptoe Therapeutics.

The use of this cytokine (G-CSF) in ovulation induction is investigational and not approved by the Food and Drug Administration (FDA) in the US. The study was entirely conducted in Japan by the authors.

The paper, titled “Granulocyte colony-stimulating factor (G-CSF) prevents luteinized unruptured follicle (LUF) caused by clomiphene treatment” shows a remarkable improvement in ovulation rate in patients suffering from LUF during ovulation induction with clomiphene citrate and hCG. Patients previously diagnosed with LUF underwent a similar stimulation regimen with the addition of G-CSF therapy. Almost all cycles (90.9%) ovulated with documented oocyte release by ultrasound after a single treatment cycle with G-CSF and about 6% (4/66) of them delivered a baby.

“LUF is a rare condition that includes the luteinization of the ovarian follicle without oocyte release. When this happens, indirect markers of ovulation, like elevation of progesterone, are present but no oocyte release occurs. This may partially explain the clinical discrepancy between “ovulation” and pregnancy rates observed in CC cycles. The chances of achieving a pregnancy during LUF cycles are highly reduced or absent,” said Professor Makinoda, M.D. Ph.D., from Kanazawa Medical University, Kanazawa, Japan, the inventor in the ‘205 Patent.

Diagnosis of LUF is difficult, controversial and only performed by serial pelvic ultrasound around ovulation and early luteal phase. There is no current approved treatment for LUF and the condition may be overcome with multiple clomiphene citrate cycle treatment attempts or more successfully with the use of assisted reproductive technologies (ART). In ART, the oocytes are retrieved from the ovary through ultrasound-guided aspiration after controlled ovarian stimulation (COS) with gonadotropins.

Clomiphene citrate is the initial treatment of choice for most anovulatory or oligo-ovulatory infertile women. In a recent trial, 475 women were observed for up to 3 cycles of CC and intrauterine insemination - IUI (Reindollar et al, 2010). There were 123 pregnancies over 1,294 cycles and 98 ongoing or live births (7.6% ongoing or live births per cycle).

In another publication (Qublan et al, 2006) a total 167 patients who underwent first CC cycle, 42 (25%) had LUF. The incidence of LUF was 56.5% in 69 patients who underwent a second CC cycle, of whom 33 patients had LUF in the first cycle with recurrence rate of 78.6%. In 56 patients who underwent 3 consecutive cycles, the incidence of LUF was 58.9% and recurrence rate of 90%. No pregnancies were recorded in patients with LUF during the study period.

The incidence of LUF is highly influenced by the type of ovulation induction therapy used and the presence of other medical conditions like endometriosis.

Steptoe Therapeutics is planning on developing G-CSF for ovulation induction. The company expects to file an Investigational New Drug (IND) application with the FDA early next year starting clinical trials in the US immediately thereafter.

“We believe that there is a chance to improve the outcomes of ovulation induction therapy with clomiphene citrate. This is a very popular entry-level therapy with low pregnancy rates per initiated cycle. Many patients have high expectations with this therapy and it happens that in many cases the ovulation signs are present but the oocyte stays trapped inside the follicle. No egg release no pregnancy and more treatment cycles are needed with increase cost emotionally and financially,” said Dr. Eduardo Kelly, the company CEO, a Reproductive Endocrinologist and Embryologist with 24 years of experience in the reproductive medicine field.

About Infertility
Infertility affects about 7.3 million women and their partners in the U.S., about 12% of the reproductive-age population (Source: National Survey of Family Growth, CDC 2002). Irregular or abnormal ovulation accounts for approximately 25 percent of all female infertility problems. Clomiphene citrate therapy is widely used among OBGYNs and Reproductive Endocrinologists. The Company estimates that about 700,000 CC treatment cycles are prescribed in the US. Failure to conceive after 3 to 4 successful CC-induced ovulation cycles is indication for further evaluation to exclude other contributing causes of infertility, particularly in women >35 years of age (ASRM 2013).

About Steptoe Therapeutics
Steptoe Therapeutics is a small privately owned Biotech Company focused on developing new therapies for infertility patients. The Company’s patented technology includes the use of a cytokine (G-CSF) to prevent and treat a condition called Luteinizing Unruptured Follicle (LUF) caused by the fertility drug clomiphene citrate. Steptoe Therapeutics follows a virtual company model keeping development cost low using the talent of recognized leaders in reproductive medicine. For more information visit http://www.steptoetherapeutics.com.

Contact:
Eduardo Kelly MD
Chief Executive Officer
Steptoe Therapeutics, Inc.
10 Keithway, Suite 3
Hingham, MA 02043
eduardo(at)steptoetherapeutic(dot)com
508-631-4254

Eduardo Kelly MD, Steptoe Therapeutics, Inc., http://www.steptoetherapeutics.com, +1 508-631-4254, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.